• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

    5/1/24 8:30:37 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERU alert in real time by email

    MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 second quarter financial results and to provide a business update.

    The audio webcast will be accessible under the Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company's website for approximately three months. A telephonic replay will be available at approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), passcode 8861692, for one week.

    About Veru Inc.

    Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The Company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin.

    Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting.

    Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The Company does not intend to undertake further development of sabizabulin for the treatment of viral-induced ARDS until we obtain funding from government grants, pharmaceutical company partnerships, or other similar third-party external sources.

    The Company also has an FDA-approved commercial product, the FC2 Female Condom® (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections.

    Forward-Looking Statements

    This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to whether and when the planned phase 2b trial of enobosarm discussed above will commence or produce topline data or patients will progress into the extension study, the planned design, timing, endpoints, patient population and patient size of such trial and whether such trial will successfully meet any of its endpoints, whether enobosarm will enhance weight loss or preserve muscle in, or meet any unmet need for, obesity patients and whether it will enhance weight loss, and whether the Company will be successful in its transformation into a late stage biopharmaceutical company focused on obesity and oncology. The words "anticipate," "believe," "could," "expect," "intend," "may," "opportunity," "plan," "predict," "potential," "estimate," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Company's current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward-looking statements contained in this press release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the risks that are detailed in the Company's periodic reports filed with the SEC, including the Company's Form 10-K for the year ended September 30, 2023, as amended by the Form 10-K/A.

    Investor and Media Contact:

    Samuel Fisch

    Executive Director, Investor Relations and Corporate Communications

    Email: [email protected]



    Primary Logo

    Get the next $VERU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERU

    DatePrice TargetRatingAnalyst
    5/14/2024$5.00Buy
    B. Riley Securities
    3/28/2024$3.00Outperform
    Raymond James
    6/7/2023$1.00Underperform → Hold
    Jefferies
    More analyst ratings

    $VERU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Veru with a new price target

      B. Riley Securities initiated coverage of Veru with a rating of Buy and set a new price target of $5.00

      5/14/24 8:03:44 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Veru with a new price target

      Raymond James initiated coverage of Veru with a rating of Outperform and set a new price target of $3.00

      3/28/24 7:50:24 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru upgraded by Jefferies with a new price target

      Jefferies upgraded Veru from Underperform to Hold and set a new price target of $1.00

      6/7/23 7:41:34 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Veru Participates in a Virtual Investor KOL Connect Segment

      -- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the release of a Virtual Investor KOL segment featuring Louis J. Aronne, MD, FACP. As part of the segment, Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru and Dr. Aronne discussed obesity and GLP-1s, the current treatment landscape and areas of unmet need, highlighting Veru'

      5/8/25 9:25:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

      --Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for

      5/8/25 6:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

      MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Thursday, May 8, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 second quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. A

      5/1/25 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Leadership Updates

    Live Leadership Updates

    See more
    • Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

      MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and

      6/1/23 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

      MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). "Today's appointment of Dr. Ho as Chairman of Veru's SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases," said Mitchell Steiner, M.D., Chairman, Presi

      1/10/23 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

      MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru's Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhan

      8/19/22 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ENTADFI issued to VERU INC

      Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

      12/13/21 8:12:46 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hyun Grace

      4 - VERU INC. (0000863894) (Issuer)

      5/8/25 3:57:21 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Katzovitz Loren Mark

      4 - VERU INC. (0000863894) (Issuer)

      5/8/25 3:49:39 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Admin Officer and CFO Greco Michele

      4 - VERU INC. (0000863894) (Issuer)

      5/8/25 3:39:39 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rankowitz Michael L bought $84,351 worth of shares (150,000 units at $0.56), increasing direct ownership by 150% to 250,000 units (SEC Form 4)

      4 - VERU INC. (0000863894) (Issuer)

      2/20/25 10:00:11 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fisch Harry bought $5,000 worth of shares (4,000 units at $1.25), increasing direct ownership by 0.52% to 774,736 units (SEC Form 4)

      4 - VERU INC. (0000863894) (Issuer)

      5/28/24 5:04:02 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barnette K Gary bought $6,696 worth of shares (5,000 units at $1.34) (SEC Form 4)

      4 - VERU INC. (0000863894) (Issuer)

      5/24/24 6:57:00 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Veru Inc.

      PRE 14A - VERU INC. (0000863894) (Filer)

      5/9/25 4:15:24 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Veru Inc.

      10-Q - VERU INC. (0000863894) (Filer)

      5/8/25 11:51:12 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - VERU INC. (0000863894) (Filer)

      5/8/25 7:01:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Financials

    Live finance-specific insights

    See more
    • Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

      --Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for

      5/8/25 6:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

      MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Thursday, May 8, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 second quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. A

      5/1/25 8:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

      --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function-- -- The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed-- --Topline results of the Phase 2b extension maintenance study to reduce fat regain following discontinuation of GLP-1 RA are expected in the second quarter of calendar 2025-- --Company announces new cardiometabolic indication for sabiza

      2/13/25 6:30:00 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Veru Inc.

      SC 13G/A - VERU INC. (0000863894) (Subject)

      11/12/24 9:34:37 AM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Veru Inc.

      SC 13G/A - VERU INC. (0000863894) (Subject)

      11/4/24 4:19:00 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Veru Inc.

      SC 13G - VERU INC. (0000863894) (Subject)

      4/24/24 4:16:01 PM ET
      $VERU
      Biotechnology: Pharmaceutical Preparations
      Health Care